Sana Biotechnology, Inc. (SANA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SANA Stock Price Chart Interactive Chart >
SANA Price/Volume Stats
| Current price | $4.81 | 52-week high | $9.60 |
| Prev. close | $4.61 | 52-week low | $3.15 |
| Day low | $4.55 | Volume | 1,167,200 |
| Day high | $4.92 | Avg. volume | 1,005,311 |
| 50-day MA | $4.28 | Dividend yield | N/A |
| 200-day MA | $5.91 | Market Cap | 917.39M |
Sana Biotechnology, Inc. (SANA) Company Bio
Sana Biotechnology, Inc. operates as a biotechnology company. The Company focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology replaces damaged cells and tissues and treats broad array of diseases.
Latest SANA News From Around the Web
Below are the latest news stories about SANA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate SANA as an investment opportunity.
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of |
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual MeetingTransplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems Allogeneic HIP CAR T cells can be produced with novel gene editing platform CRISPR/Cas12b at large scale and high gene-editing efficiency HIP-modified allogeneic BCMA-targeted CAR T cells demonstrate in vitro efficacy and cytokine production against BCMA+ target cells against multiple myeloma |
Sana Biotechnology to lay off 15% of its employeesSeattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is laying off about 15% of its staff, according to a Nov. 29 Securities and Exchange Commission filing. The biotech said it was stopping further investment in SC187, its program aimed at heart failure. Sana said in a Nov. 2 SEC filing that it had 494 full-time employees as of Sep. 30, meaning roughly 74 employees are affected by the layoffs. |
Once valued at $6 billion, Sana Biotechnology plans to cut 15% of workforceThe company earlier this year decided to shift manufacturing from Fremont to near its Seattle headquarters. |
Sana Biotechnology Outlines Pipeline Prioritization, Reduces WorkforceSana Biotechnology Inc (NASDAQ: SANA) announced a portfolio prioritization expected to provide a cash runway into 2025. The resulting changes include focusing its second HIP-modified allogeneic CAR T program on targeting CD22 for CD19 CAR T failures, halting further internal investment in its SC187 program (cardiomyocytes for heart failure), and stage-gating certain platform investments based upon clinical progress in humans. The prioritization and restructuring reduced the company's headcount b |
SANA Price Returns
| 1-mo | 26.91% |
| 3-mo | -19.83% |
| 6-mo | -21.15% |
| 1-year | -40.32% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 21.77% |
| 2022 | -74.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...